Press Release: FDA Approves New Bladder Cancer Treatment

May 18, 2016
by Andrea Maddox-Smith

The Bladder Cancer Advocacy Network (BCAN) applauds the U.S. Food and Drug Administration (FDA) approval of an innovative, first-of-its-kind bladder cancer treatment, establishing a brand new class of therapy for the disease. Genentech, a member of the Roche Group, produced this new treatment, TECENTRIQ™ (atezolizumab), which allows the body’s immune system to work more effectively to fight cancer.

Read More...

Meet BCAN Volunteer Nancy Lindsey

May 17, 2016
by Jeanne Mahoney

I was diagnosed with bladder cancer in 2006. I had blood in my urine – the specialists thought of everything else possibly causing this — but I believed there was more to it. I got a second opinion, and then nine months later came a confirmation of bladder cancer.

Read More...

Taking the Necessary Steps to Make the Cancer Moonshot Work

March 15, 2016
by Diane Quale

Earlier last month, President Obama tasked Vice President Biden with leading a new national initiative to work toward a cure for cancer and recently announced that the White House would allot an initial $1 billion to the project, promising to pool more funds over time. By all accounts, this is a reminder of the vast momentum that exists, as well as the gravity of the challenges that lie ahead and why it ranks as one of the most difficult endeavors in human history.

Read More...

BCAN at ASCO GU

January 11, 2016
by Stephanie Chisolm

BCAN just returned from the American Society of Clinical Oncology’s 2016 Genitourinary Cancer Symposium held January 7-9 in San Francisco.

Read More...